Dabrafenib
Overview
Dabrafenib mesylate is a kinase inhibitor. The chemical name for dabrafenib mesylate is N-{3- [5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-
difluorobenzene sulfonamide, methanesulfonate salt. it is used for the treatment of patients with unresectable or metastatic melanoma with braf V600E mutation.
Categories
- 8 Antineoplastics, immunomodulators and drugs used in palliative care
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Dabrafenib's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 150 mg | 150 (150) | 2 hourly | PO | as a single agent |
| 150 mg | 150 (150) | 2 hourly | PO | in combination with trametinib 2mg once daily |
Paedriatic Dosage (20kg)
|
| No data regarding the Paedriatic dosage details of Dabrafenib is available. |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Dabrafenib is available. |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
No data regarding the pathological interferences produced by Dabrafenib is available.
Back to top
Brands / Trade Names of
Dabrafenib
Back to top
Previous Drug Generic - Next Drug Generic